Case Solution for Sanofi-Aventis’s Tender Offer for Genzyme

Complete Case details are given below :

Case Name :      Sanofi-Aventis’s Tender Offer for Genzyme
Authors :           Kenneth Eades, Pedro Matos, Dmitriy Aleyev, Chong Xu
Source :             Darden School of Business
Case ID :           UV6874
Discipline :        Finance
Case Length :    29 pages
Solution Sample availability : YES
Plagiarism : NO (100% Original work)
Description for case is given below :
This case is designed to be part of an MBA corporate finance class. In October 2010, Henri Termeer, the chairman and CEO of Genzyme (a top-five biotechnology company), received a letter from the CEO of Sanofi-Aventis (a large French pharmaceutical company) announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. To estimate Genzyme’s fundamental value, Termeer and his finance team would need to conduct a discounted cash flow (DCF) and other valuation analyses. Termeer needed to be well prepared for the board meeting during which the response to the offer would be formulated.
Click Here to place your order
Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.
Case Solutions Hub

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s